Sunday, September 29, 2019 11:40:27 AM
______________________________________________________________________________________________
Ern Haven Youtube
Valarie Lynch
The Case for Provisional Approval
AUSTRALIAN DEMENTIA FORUM
Accelerating research. Enhancing collaboration. Creating change.
Hotel Grand Chancellor Hobart, 13-14 June 2019
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151146610
The timeline and requirements for provisional approval in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148221459
Provisional approval in Australia may not require completion of the P3.. (links thanks to JonJones325)
https://www.tga.gov.au/publication/provisional-determination-eligibility-criteria
https://www.tga.gov.au/publication/provisional-determination
https://www.tga.gov.au/presentation-provisional-approval-pathway-prescription-medicines
December 2018 discussion of Possible Provisional approval in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145445997
Definition of Major Therapeutic Advance in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144734105
Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144651100
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144731123
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144982778
“These findings show Australians want future access to breakthrough medicines. What is critical is to balance this innovation and affordability with the expectations of Australians. This will challenge some of our long-standing healthcare policies. We only have to look at the evolution in precision medicine and the impact targeted therapies can have on health outcomes and costs.” (from kevli33)
https://medicinesaustralia.com.au/from-the-chief-executive/new-findings-confirm-australians-place-high-value-on-the-pbs-but-acknowledge-its-shortfalls/
Discussion of possible commercial sales under Aussie SAS program:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149077207
More info on SAS:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=1471727
Australia sees the need for population based screening for dementia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148875697
Australia - possible preparations down under
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151146610
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150922608
The Australian attitude toward healthcare is 180 degrees away from the U.S. for profit system.
AUSTRAILIA TGA is different from the U.S. FDA
https://www.slideshare.net/TherapeuticGoodsAdministration/clinical-trials-tga-role
Top 20 pharmas with an Australian company that would make a good Anavex partner:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148731195I
See note on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148733750
Australia may get us Canada:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148710704&txt2find=tga
Aussie P2/3 - link to study:
https://www.australianclinicaltrials.gov.au/anzctr/trial/NCT03790709
AIBL study (Australian Imaging Biomarker Lifestyle Study)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148157259&txt2find=AIBL
Study was cited by Missling:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154210
April 5 2019 presentation to Australian healthcare workers concerning new trial approval protocol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148220574
On the possibility of miss diagnosis in Australia.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065519
2014 paper on diagnostic accuracy in Alzheimer's in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065519
The facts about clinical trials performed in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148074963
Feedback from Down Under - KaRa MINDS Institute participating as of 10/19/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146469112
Speeding up trials in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144956115
Recent AVXL News
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM